Key result
Polyherbal formulation reduces weight, insulin resistance, and myocardial lipid deposition in high-fat-diet rats.
Why the study?
Obesity-associated cardiomyopathy arises from complex interactions of systemic metabolic disturbances, myocardial lipid overload, and impaired insulin signalling.
Does a polyherbal formulation improve cardiometabolic parameters and attenuate cardiomyopathy in a high-fat-diet-induced obesity rat model?
Does a polyherbal formulation improve cardiometabolic parameters and attenuate cardiomyopathy in a high-fat-diet-induced obesity rat model?
A polyherbal formulation attenuates high-fat-diet-induced obesity cardiomyopathy in rats by modulating insulin signaling and cardiac lipotoxicity pathways.
PHF cardiometabolic effects in rats should not change practice; leaves open human translation for obesity-associated cardiomyopathy.
Obesity-associated cardiomyopathy (Ob-CM) arises from a complex interaction of systemic metabolic disturbances, myocardial lipid overload, and impaired insulin signalling. This study evaluated the cardiometabolic efficacy of a polyherbal formulation (PHF) comprising Vernonia amygdalina , Cissus quadrangularis , Eryngium foetidum , and Aristolochia indica in a high-fat-diet (HFD)-induced Ob-CM rat model. HFD rats exhibited marked adiposity, dyslipidemia, insulin resistance, inflammatory imbalance, and myocardial triglyceride accumulation. PHF administration significantly reduced body weight, visceral fat, serum lipids, free fatty acids, and HOMA-IR, while restoring adiponectin, reducing pro-inflammatory cytokines, and lowering cardiac injury biomarkers. PHF also attenuated myocardial lipid deposition and preserved cardiac histoarchitecture. Mechanistically, PHF reinstated PI3K/IRS-1/Akt/GLUT4-mediated insulin signalling and corrected PPARα/SREBP-1c-driven lipotoxicity by enhancing AMPK-CPT1-mediated fatty acid oxidation and reducing de novo lipogenesis. These results indicate that PHF confers cardioprotection through coordinated metabolic reprogramming, supporting its potential as an integrative, multi-target therapeutic strategy for obesity-related cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Chandrasekharnath et al. (2026) studied Obesity-associated cardiomyopathy. Polyherbal formulation (PHF) vs. High-fat-diet (HFD) control was evaluated on Cardiometabolic efficacy, including body weight, visceral fat, serum lipids, and myocardial lipid deposition. Polyherbal formulation administration significantly reduced body weight, visceral fat, and insulin resistance, and attenuated myocardial lipid deposition in a high-fat-diet-induced rat model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: